BRPI1008058A8 - uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa - Google Patents
uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosaInfo
- Publication number
- BRPI1008058A8 BRPI1008058A8 BRPI1008058A BRPI1008058A BRPI1008058A8 BR PI1008058 A8 BRPI1008058 A8 BR PI1008058A8 BR PI1008058 A BRPI1008058 A BR PI1008058A BR PI1008058 A BRPI1008058 A BR PI1008058A BR PI1008058 A8 BRPI1008058 A8 BR PI1008058A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibiotics
- likelihood
- reduce
- bowel syndrome
- irritable bowel
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 208000002551 irritable bowel syndrome Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15177209P | 2009-02-11 | 2009-02-11 | |
| PCT/US2010/023873 WO2010093776A1 (en) | 2009-02-11 | 2010-02-11 | Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1008058A2 BRPI1008058A2 (pt) | 2016-03-15 |
| BRPI1008058A8 true BRPI1008058A8 (pt) | 2018-03-27 |
Family
ID=42562059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008058A BRPI1008058A8 (pt) | 2009-02-11 | 2010-02-11 | uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110294726A1 (pt) |
| EP (1) | EP2396029A4 (pt) |
| AU (1) | AU2010213773B2 (pt) |
| BR (1) | BRPI1008058A8 (pt) |
| CA (1) | CA2752020A1 (pt) |
| CL (1) | CL2011001943A1 (pt) |
| MX (1) | MX2011008354A (pt) |
| WO (1) | WO2010093776A1 (pt) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10352944B2 (en) | 2013-10-09 | 2019-07-16 | Cedars-Sinai Medical Center | Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease |
| US10466254B2 (en) | 2012-09-17 | 2019-11-05 | Cedars-Sinai Medical Center | Method of measuring a level of anti-vinculin antibodies in a biological sample |
| US10690679B2 (en) | 2014-10-09 | 2020-06-23 | Cedars-Sinai Medical Center | Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
| US12222352B2 (en) | 2017-01-30 | 2025-02-11 | Cedars-Sinai Medical Center | Diagnosis of scleroderma |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| US9110081B2 (en) | 2009-02-11 | 2015-08-18 | Cedars-Sinai Medical Center | Antibody to cytolethal distending toxin of Campylobacter jejuni |
| US11693009B2 (en) | 2009-02-11 | 2023-07-04 | Cedars-Sinai Medical Center | Methods for detecting post-infectious irritable bowel syndrome |
| EP2493471B1 (en) | 2009-10-26 | 2019-11-27 | Thomas Julius Borody | Novel enteric combination therapy |
| CN103562240B (zh) * | 2011-06-03 | 2017-02-15 | 巴斯夫欧洲公司 | 连续制备吸水性聚合物颗粒的方法 |
| AU2013212008A1 (en) | 2012-01-25 | 2014-07-10 | Alfa Wassermann S.P.A. | Rifaximin derivative and uses thereof |
| EP2906711B1 (en) * | 2012-10-10 | 2018-09-19 | Stc.Unm | Methods for diagnosing bacterial infections |
| CN119454720A (zh) * | 2016-03-24 | 2025-02-18 | 帕拉特克Spv2有限责任公司 | 用于治疗和预防艰难梭菌感染的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992006690A1 (en) * | 1990-10-22 | 1992-04-30 | Borody Thomas J | Treatment of non-inflammatory and non-infectious bowel disorders |
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US20030157159A1 (en) * | 2002-01-15 | 2003-08-21 | Franklin Lanny Udell | Prevention and treatment of digestive tract infections |
| ATE448775T1 (de) * | 2002-08-29 | 2009-12-15 | Activbiotics Pharma Llc | Rifalazil zur behandlung von infektionen mit clostridium difficile |
| CN1914322B (zh) * | 2003-12-05 | 2012-05-30 | 扶桑药品工业株式会社 | 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测 |
| US20090233888A1 (en) * | 2005-03-23 | 2009-09-17 | Usc Stevens, University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
| MX2009001342A (es) * | 2006-08-02 | 2009-08-31 | Salix Pharmaceuticals Inc | Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion. |
| JP5755878B2 (ja) * | 2007-07-06 | 2015-07-29 | ルパン リミテッドLupin Limited | リファキシミンの薬剤組成物 |
| PT2252148T (pt) * | 2008-02-26 | 2020-01-23 | Salix Pharmaceuticals Ltd | Métodos de tratamento da síndrome do intestino irritável |
-
2010
- 2010-02-11 US US13/148,215 patent/US20110294726A1/en not_active Abandoned
- 2010-02-11 EP EP10741713A patent/EP2396029A4/en not_active Withdrawn
- 2010-02-11 BR BRPI1008058A patent/BRPI1008058A8/pt not_active Application Discontinuation
- 2010-02-11 AU AU2010213773A patent/AU2010213773B2/en not_active Ceased
- 2010-02-11 CA CA2752020A patent/CA2752020A1/en not_active Abandoned
- 2010-02-11 WO PCT/US2010/023873 patent/WO2010093776A1/en not_active Ceased
- 2010-02-11 MX MX2011008354A patent/MX2011008354A/es not_active Application Discontinuation
-
2011
- 2011-08-10 CL CL2011001943A patent/CL2011001943A1/es unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10466254B2 (en) | 2012-09-17 | 2019-11-05 | Cedars-Sinai Medical Center | Method of measuring a level of anti-vinculin antibodies in a biological sample |
| US10352944B2 (en) | 2013-10-09 | 2019-07-16 | Cedars-Sinai Medical Center | Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease |
| US10690679B2 (en) | 2014-10-09 | 2020-06-23 | Cedars-Sinai Medical Center | Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease |
| US12222352B2 (en) | 2017-01-30 | 2025-02-11 | Cedars-Sinai Medical Center | Diagnosis of scleroderma |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2396029A1 (en) | 2011-12-21 |
| EP2396029A4 (en) | 2012-08-08 |
| WO2010093776A1 (en) | 2010-08-19 |
| CA2752020A1 (en) | 2010-08-19 |
| AU2010213773B2 (en) | 2014-07-17 |
| CL2011001943A1 (es) | 2012-02-03 |
| AU2010213773A1 (en) | 2011-08-25 |
| BRPI1008058A2 (pt) | 2016-03-15 |
| US20110294726A1 (en) | 2011-12-01 |
| MX2011008354A (es) | 2011-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008058A2 (pt) | terapia antibiótica para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa | |
| BRPI1014262A2 (pt) | anticorpos específicos para caderina-17 | |
| BRPI1006519A2 (pt) | formulação de anticorpos | |
| BRPI1014316A2 (pt) | composição, e, uso de uma composição | |
| IL218328A (en) | Parabolic trough collector | |
| EP2414948A4 (en) | APPLICATION SHARING | |
| EP2644185A4 (en) | IMPROPER CLEANING AGENT | |
| DK2930184T3 (da) | Dkk-1-antistoffer | |
| EP2518066A4 (en) | NOVEL THROMBOCYTE AGGREGATION INHIBITOR | |
| EP2400820A4 (en) | DEVICE PROVIDING LOADS | |
| BR112012001066A2 (pt) | mecanismo de manivela | |
| BR112012014028A2 (pt) | uso de uma composição | |
| EP2440972A4 (en) | PROJECTION SYSTEM | |
| DE112010002868A5 (de) | Doppelkupplung | |
| BRPI1015091A2 (pt) | novo uso | |
| EP2554603A4 (en) | THERMAL ELASTOMER COMPOSITION | |
| BRPI1011036A2 (pt) | uso | |
| BRPI0925002A2 (pt) | uso de uma composição para a prevenção de diarréia | |
| EP2509287A4 (en) | SLIDING AND TILTING MECHANISM | |
| DK2513115T3 (da) | Tricycliske antibiotika | |
| BR112012001837A2 (pt) | uso de fulvestrant | |
| BRPI1010740A2 (pt) | novos derivados de ciclopentano | |
| DE112010002723A5 (de) | Doppelkupplung | |
| FI20096192A0 (fi) | Kohteen valaiseminen | |
| BR112012002575A2 (pt) | utilização de uma composição. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2467 DE 17/04/2018 POR TER SIDO INDEVIDA. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal: dismissal of application maintained |